4-氨基吡啶 → 9-Bromo-5-(4-pyridylcarbamoylmethyl)-6,7-dihydro-1H, 5H-pyrido[1,2,3-de]quinoxaline-2,3-dione

HRID 52522

反应方程式

HRID 52522 反应方程式
[Br:1][C:2]1[CH:3]=[C:4]2[CH2:16][CH2:15][CH:14]([CH2:17][C:18]([OH:20])=O)[N:6]3[C:7](=[O:13])[C:8](=[O:12])[NH:9][C:10]([CH:11]=1)=[C:5]23.[NH2:21][C:22]1[CH:27]=[CH:26][N:25]=[CH:24][CH:23]=1>>[Br:1][C:2]1[CH:3]=[C:4]2[CH2:16][CH2:15][CH:14]([CH2:17][C:18](=[O:20])[NH:21][C:22]3[CH:27]=[CH:26][N:25]=[CH:24][CH:23]=3)[N:6]3[C:7](=[O:13])[C:8](=[O:12])[NH:9][C:10]([CH:11]=1)=[C:5]23

参与物

3

反应物 2

HCID 17274-氨基吡啶HCID 104723389-bromo-5-carboxymethyl-6,7-dihydro-1H, 5 H-pyrido[1,2,3-de]quinoxaline-2,3-dione

产物 1

HCID 545091029-Bromo-5-(4-pyridylcarbamoylmethyl)-6,7-dihydro-1H, 5H-pyrido[1,2,3-de]quinoxaline-2,3-dione收率 69.4%

实验过程

A procedure similar to that described in Example 51 was carried out with 9-bromo-5-carboxymethyl-6,7-dihydro-1H, 5H-pyrido[1,2,3-de]quinoxaline-2,3-dione (170 mg, 0.5 mmol) and 4-aminopyridine (60 mg, 0.64 mmol) to give 144 mg of the title compound (69%): mp>270° C.; 1H NMR (270 MHz, DMSO-d6) δ12.10 (bs, 1H), 10.90 (s, 1H), 9.04 (d, 1H, J=2 Hz), 8.50 (d, 2H, J=5.4 Hz), 8.31 (d, 1H, J=9 Hz), 7.78 (dd, 1H, J=5.4, 9 Hz), 7.24 (d, 1H, J=2 Hz), 7.19 (d, 1H, J=2 Hz), 5.17~5.28 (m, 1H), 3.05 (ddd, 1H, J=17.1, 13.5, 4.5 Hz), 2.83 (dm, 1H, J=17.1 Hz), 2.69 (d, 2H, J=7.2 Hz), 2.13 (dm, 1H, J=13.5 Hz), 1.80~1.96 (m, 1H).

来源与证据

ORD记录
ord-7ef5572e1416438ba3dc47249126b860
来源数据集
uspto-grants-1997_04
专利号
US05616586

关联笔记

加载中…